Skip to main content

Market Overview

Why Myovant Sciences Is Trading Higher Today

Why Myovant Sciences Is Trading Higher Today

Myovant Sciences Ltd (NYSE: MYOV) shares are trading higher on Tuesday, after the company, along with Gedeon Richter, announced they have entered into an exclusive license agreement for Gedeon Richter to commercialize relugolix combination tablet.

Myovant will receive $40 million upfront and up to $147 million in milestones.

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders.

Myovant Sciences shares were trading up 4.89% to $8.15 at time of publication. The stock has a 52-week high of $26.02 and a 52-week low of $4.14.


Related Articles (MYOV)

View Comments and Join the Discussion!

Posted-In: why it's movingBiotech News Contracts Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at